Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials

Autor: Bachelot, T. ^*, Ray-Coquard, I., Catimel, G., Ardiet, C., Guastalla, J.P., Dumortier, A., Chauvin, F., Droz, J.P., Philip, T., Clavel, M.

Publikováno v: In Annals of Oncology February 2000 11(2):151-156

Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck: Results of a phase II study of the EORTC Early Clinical Studies Group

Autor: Schöffski, P. ^*, Catimel, G., Planting, A.S.T., Droz, J.-P., Verweij, J., Schrijvers, D., Gras, L., Schrijvers, A., Wanders, J., Hanauske, A.R.

Publikováno v: In Annals of Oncology January 1999 10(1):119-122

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group

Autor: Hanauske, A. R., Catimel, G., Aamdal, S., ten Bokkel Huinink, W., Paridaens, R., Pavlidis, N., Kaye, S. B., te Velde, A., Wanders, J., Verweij, J.

Publikováno v: British Journal of Cancer

Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose of our studies was to determin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::cd951004431b902dda93c39b75ff3e50
http://europepmc.org/articles/PMC2074418

A dose finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors

Autor: Giaccone, G., Linn, S., Welink, J., Catimel, G., Stieltjes, H., van der Vijgh, W.J.F., Eeltink, C.M., Vermorken, J.B., Pinedo, H.M.

Publikováno v: Giaccone, G, Linn, S, Welink, J, Catimel, G, Stieltjes, H, van der Vijgh, W J F, Eeltink, C M, Vermorken, J B & Pinedo, H M 1997, ' A dose finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors ', Clinical Cancer Research, vol. 3, pp. 2005-2015 .
Clinical Cancer Research, 3, 2005-2015. American Association for Cancer Research Inc.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3a780a00763c556ce559ebd5e2e70191
https://research.vumc.nl/en/publications/7d37af16-6120-46c3-9d32-3c1ffee2c3fa

Phase II clinical trials with rhizoxin in breast cancer and melanoma

Autor: Hanauske, A. R., Catimel, G., Aamdal, S., Huinink, W. W. Ten Bokkel, Paridaens, R., Pavlidis, Nicholas, Kaye, Stanley B., Velde, A. Te, Wanders, J., Verweij, J.

Publikováno v: British journal of cancer

Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose of our studies was to determin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4485::e744a18d14c2bb29bb126f551d14d2b5
https://gnosis.library.ucy.ac.cy/handle/7/41857